Shilpa Medicare’s JV Oncosol and partner Shorla Oncology gets US FDA approval for IMKELDI
IMKELDI is the first oral liquid form of imatinib used to treat certain forms of leukemia and other cancers.
Uncategorized
Nifty 50 hits 3-week high led by HDFC Bank and Adani Group stocks
The Sensex surged 230 points to 80,234, while the Nifty gained 80 points, settling at 24,275.
SBI raises ₹50,000 crore via domestic bonds in FY25
The AT1 Bonds are rated AA+ with a stable outlook, while both Tier 2 and Long-Term Bonds are rated AAA with a stable outlook.
NTPC Green Energy targets 19,000 MW capacity by March 2027
CMD Gurdeep Singh said the target is to reach renewable capacity of 60 GW by 2032 while optimising funding costs through its robust credit ratings.
Suprajit Engineering gains over 4% on signing MoU with Japan’s Chuo Spring
The collaboration includes a 50:50 joint venture (JV) in India aimed at designing, manufacturing, and supplying transmission cables.
RVNL, IRFC shares gain up to 5% as railway stocks move in tandem with PSU rebound
Shares of railway companies are trading with gains between 2% and 5%.
Shares of this ₹650 crore NBFC are up 33% in three sessions after Morgan Stanley buys stake
Besides Think India Opportunities Master Fund, other FPIs whose names feature in the shareholding list include the UPS Group Trust with a 1.75% stake and Vikasa India EIF I Fund with a 4.09% stake.
As Nifty IT hits another record, here are Bernstein’s top two tech stock picks
As the IT index witnesses an uptrend, Bernstein continues to see the beginning of an up-cycle trend as growth recovers, with BFSI inflects and AI deals scaling up in the IT services industry. It believes FY26 will be a normalised…
Siemens shares rise 5% on operationally strong Q4; what should investors do?
Brokerage firm Nuvama Institutional Equities said the company’s big ticket-size orders will materialise over the next 12–24 months.
Why Sanjeev Prasad thinks Indian market valuations are misleading
Sanjeev Prasad believes valuations will eventually catch up, and there could be corrections in several midcap and small-cap stocks, many of which are still overvalued even after recent price declines.